

**CENTERS FOR DISEASE CONTROL AND PREVENTION (Draft)**  
**ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES**  
**MARRIOTT CENTURY CENTER HOTEL**  
**ATLANTA, GEORGIA**  
**FEBRUARY 24-25, 2004**

<b><u>AGENDA ITEM</u></b>	<b><u>PURPOSE/ACTION</u></b>	<b><u>PRESIDER/PRESENTER(s)</u></b>
<b>February 24</b>		
8:30    Welcome		Dr. M. Levin (Chair, ACIP) Dr. S. Hadler (CDC, OD)
<b>Influenza Session</b>		
9:00    Report of the NVAC/ACIP Joint Working Group on an OPV Stockpile	Information	Dr. C. Helms
9:45    Introduction of Influenza	Information	Dr. K. Fukuda (NCID) Dr. R. Zimmerman
<b>Overview of 2003-04 season</b>		
10:00    Epidemiology and Surveillance	Information	Ms. L. Brammer (NCID) Dr. K. Fukuda (NCID)
10:15    Overview and Summary of CDC response activities	Information Discussion	TBD
10:30 <b>BREAK</b>		
11:00    Impact in children		Dr. T. Uyeki (NCID)
11:20    Vaccine effectiveness		Dr. C. Bridges (NIP)
11:40    Surveys		DHQP
12:00    Summary of vaccine supply issues and CDC actions		Dr. R. Strikas (NIP)
12:20    Summary of antiviral purchase	Information Discussion	Dr. B. Schwartz (NIP)
12:30 <b>LUNCH</b>		
<b>LAIIV-related issues</b>		
1:30    Summary of its reception and future product plans	Information	MedImmune
1:40    Summary of difficult questions that arose related to its use	Discussion Information	IB
1:55    Adult shedding data from Vanderbilt	Information	Tom Talbot (Vanderbilt)
2:15    Language changes for 2004	Discussion Vote	Dr. S. Harper
2:45    Changes in 2004 document 6-23 months Pregnant women LAIIV	Discussion Vote	Dr. S. Harper
3:45 <b>BREAK</b>		
4:15    Should ACIP begin deliberating universal flu vaccination?		
Overview and Summary of issues Proposed process	Information	Dr. K. Fukuda (NCID)
4:40    Comments from FDA		
4:45    Discussion		Dr. K. Fukuda (NCID) Dr. R. Zimmerman
5:15 <b>ADJOURN</b>		

AGENDA ITEM  
February 25

PURPOSE/ACTION

PRESIDER/PRESENTER(s)

8:00	Unfinished Business from Previous Day		
8:30	Childhood Immunization Schedule Update	Information	Dr. G. Wallace (NIP)
9:00	Smallpox Program Overview Consideration in the timing of revaccination for smallpox	Information Discussion	Dr. R. Strikas (NIP) Dr. L. Quick (NIP)
9:30	Report from ACIP Vaccine Safety Working Group	Discussion Information	Dr. J. Neff
10:00	<b>BREAK</b>		
10:30	Update on IOM Report	Information	Dr. M. Levin (ACIP Chair)
10:45	Meningococcal Work Group Update	Information	Dr. R. Finger
11:00	Epidemiology of Meningococcal Disease in the U.S.	Information Discussion	Dr. N. Rosenstein (NCID)
11:30	Vaccine Safety Update Metro Atlanta MMR and Autism Study VSD thimerosal screening study VSD thimerosal follow-up study	Information	Dr. R. Chen (NIP) Dr. F. DeStefano (NIP)  Dr. W. Thompson (NIP)
12:15	<b>LUNCH</b>		
1:15	UPDATES Department of Defense Food and Drug Administration National Institutes of Health National Vaccine Program Office Vaccine Injury Compensation Program National Center for Infectious Diseases National Immunization Program	Information	Dr. S. Phillips (DoD) Dr. N. Baylor (FDA) Dr. G. Cullin (NIH, NIAID) Dr. B. Gellin (NVPO) Dr. G. Evans (HRSA) Dr. A. Mawle (NCID, OD) Dr. W. Orenstein (NIP, OD)
2:30	Public Comment		
2:45	ADJOURN		

2/25/2004